

ONCOVID-19 - Prospective analysis of morbi-mortality of patients with cancers in active phase of treatment suspected or diagnosed of a SARS-CoV-2 infection

Head :ASSAAD Souad

Last update : 12/11/2020 | Version : 1 | ID : 73838

General	
Identification	
Detailed name	Prospective analysis of morbi-mortality of patients with cancers in active phase of treatment suspected or diagnosed of a SARS-CoV-2 infection
Sign or acronym	ONCOVID-19
General Aspects	
Medical area	Cancer research
Study in connection with Covid-19	Yes
Pathology (details)	Any primary tumor with suspicion of SARS-CoV-2 infection
Scientific investigator(s) (Contact)	
Name of the director	ASSAAD
Surname	Souad
Organization	Centre Léon Bérard
Collaborations	
Participation in projects, networks and consortia	Yes
Funding	
Funding status	Mixed
Details	Big pharma and ANR Flash COVID
Governance of the database	
Sponsor(s) or organisation(s) responsible	Centre Léon Bérard

Organisation status	Private
Presence of scientific or steering committees	Yes
Additional contact	
Main features	
Type of database	
Type of database	Others
Specify	Clinical database
Database objective	
Main objective	<p>The primary objective is to describe the mortality of cancer patients under active anticancer treatment who underwent diagnostic procedures (positive or negative) for a suspicion of COVID-19.</p> <p>The primary endpoint will be the mortality rate, defined as the proportion of patients who are dead 28 days after the date of the diagnostic procedure for the 2 cohorts of patients (positive and negative).</p>
Inclusion criteria	<ul style="list-style-type: none"> - Confirmed diagnosis of any type of solid or hematologic tumor; - Ongoing anticancer treatment (cytotoxic, targeted therapy, immunotherapy or loco regional procedure, including radiotherapy, surgery or interventional radiology procedure) at the time of inclusion or within the last 3 months prior to inclusion (last treatment administration or last loco regional procedure) ; - Patient with suspicion of COVID-19 (clinical symptoms of COVID-19 including fever (>38°C) and/or respiratory tract symptoms), either confirmed or not. <p>Note 1: Patients must have underwent diagnostic procedures: diagnostic test (positive or negative) and/or chest imaging.</p> <p>Note 2: Patients will be eligible regardless of the presence of a neutropenia (either febrile or not)</p> <ul style="list-style-type: none"> - Patient and/or family did not decline data collection after complete information (information sheet)
Population type	
Age	Adulthood (19 to 24 years)

	Adulthood (25 to 44 years) Adulthood (45 to 64 years) Elderly (65 to 79 years) Great age (80 years and more)
Population covered	Sick population
Pathology	II - Neoplasms
Gender	Male Woman
Geography area	National
Detail of the geography area	France (Comprehensive cancer centers, university hospitals and general hospitals)
Data collection	
Dates	
Date of first collection (YYYY or MM/YYYY)	2020
Date of last collection (YYYY or MM/YYYY)	2020
Size of the database	
Size of the database (number of individuals)	[1000-10 000[individuals
Details of the number of individuals	1150
Data	
Database activity	Data collection completed
Type of data collected	Clinical data
Clinical data (detail)	Medical registration
Details of collected clinical data	Cancer history, current cancer treatments, COVID-19 diagnosis and vital status
Presence of a biobank	No
Procedures	
Data collection method	Investigational sites

Quality procedure(s) used	Remote monitoring
Participant monitoring	Yes
Details on monitoring of participants	Day 28 (primary outcome and) Vital status update for all participants at the Last Patient Last Visit
Links to administrative sources	No

Promotion and access
Promotion
Access